Macrocyclic Inhibitors for Hepatitis C Viral Load Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral therapies for chronic hepatitis C virus (HCV) infections, particularly those targeting the Flaviviridae family, are inadequate due to high viral production and mutability, with existing treatments like ribavirin and interferon-alpha showing limited effectiveness and toxicity.
Innovation Solution
Development of novel macrocyclic compounds represented by Formula I, which can be administered as pharmaceutical compositions or in combination with other therapeutic agents to reduce viral load or clear viral RNA in patients, targeting Flaviviridae and potentially Coronaviridae infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ribavirin and interferon-alpha are used for treating chronic HCV infections, then some viral reduction effect is achieved, but treatment effectiveness is limited and toxicity increases
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of sanglifehrin macrocycles through systematic variations in substituents, ring sizes, and functional groups to optimize both antiviral effectiveness and safety profile. This is evident in the extensive structural modifications described in the patent that aim to improve upon existing therapies while reducing toxicity.
2Reliability
If combination therapy with interferon-alpha and ribavirin is administered, then persistent benefit is achieved in less than half of patients, but treatment complexity increases
Solution Approach 1:
The patent extracts the core antiviral mechanism from complex combination therapies by focusing on macrocyclic compounds that target specific viral processes. This extraction approach seeks to achieve persistent benefit through a more focused mechanism rather than relying on multiple agents working through different pathways, thereby potentially simplifying the treatment regimen.
Solution Approach 2:
The macrocyclic compounds described in the patent are designed with multi-functional capabilities, including antiviral activity, immunomodulatory effects, and anti-inflammatory properties. This multi-functionality allows a single compound to address multiple aspects of viral infection simultaneously, potentially replacing the need for complex combination therapies.
3Reliability
If novel macrocyclic compounds are developed to improve treatment effectiveness, then antiviral activity increases, but development complexity and time requirements increase
Solution Approach 1:
The patent applies segmentation by dividing the macrocyclic structure into distinct modular components that can be independently optimized and assembled. This modular approach to structure-activity relationship development allows systematic improvement of antiviral activity while managing development complexity through organized exploration of structural variations.
Solution Approach 2:
The patent employs preliminary action through extensive in silico modeling, computational chemistry, and pre-clinical testing of macrocyclic compounds before advancing to clinical trials. This preliminary characterization of structure-activity relationships and optimization of candidate compounds reduces development risks and accelerates the path to effective therapies.
Data Source
AI summary
Provided are compounds of Formula I:and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of virus infections, particularly hepatitis C infections.